Stockscreener 앱 받기
0.742
3.91%
0.0279
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart appoints new board member with healthcare expertise By Investing.com - Investing.com South Africa
Vaxart appoints new board member with healthcare expertise - Investing.com
Vaxart Announces Board Changes with New Appointment - TipRanks
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors - GlobeNewswire
Vaxart (NASDAQ: VXRT) Receives Positive Recommendation for Phase 2b COVID-19 Vaccine TrialOn January 13, 2025, Vaxart, Inc. announced that an independent Data Safety Monitoring Board has recommended that the Company’s Phase 2b clinical trial - Defense World
Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Vaxart advances Phase 2b COVID-19 vaccine trial By Investing.com - Investing.com Canada
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - GlobeNewswire
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs - GlobeNewswire
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Nasdaq Q-50 Index (NXTQ) QuotePress Release - The Globe and Mail
Vaxart Inc (VXRT-Q) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
TSX Global Gold EW Index (TXGE) QuotePress Release - The Globe and Mail
KBW Premium Yield Equity REIT Index (KYX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Vaxart advances Phase 2b COVID-19 vaccine trial - Investing.com
Vaxart Advances COVID-19 Oral Vaccine to 10,000-Patient Trial, Expands Pipeline with Norovirus Program - StockTitan
Vaxart's Oral COVID Vaccine Advances: Safety Board Backs Phase 2b Trial Expansion to 10,000 Patients - StockTitan
Deutsche Bank Ag (DB-N) QuotePress Release - The Globe and Mail
Ast Spacemobile Inc (ASTS-Q) QuotePress Release - The Globe and Mail
Vaxart (STU:NB11) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Vaxart spikes as B. Riley upgrades at long last after BARDA funding - MSN
Geode Capital Management LLC Acquires 346,725 Shares of Vaxart, Inc. (NASDAQ:VXRT) - Defense World
Andrei Floroiu Vaxart CEO Rating - Comparably Workplace Insider
Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47% - Simply Wall St
Vaxart Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Vaxart (NASDAQ: VXRT) Increases Funding for COVID-19 Vaccine Trial - Defense World
Vaxart project agreement change ups funding for oral COVID vaccine candidate - Yahoo Finance
Vaxart secures additional $4.6M for COVID-19 pill vaccine trial - Investing.com Nigeria
Vaxart secures additional $4.6M for COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
XTX Topco Ltd Boosts Position in Vaxart, Inc. (NASDAQ:VXRT) - Defense World
Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try - Law360
Vaxart Investors Get Class Status on Second Try Against Insider - Bloomberg Law
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
No time to wait on development of second-generation vaccines - The Hill
Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says - Law360
Vaxart Hits Key Milestone in Phase 2b Oral COVID Vaccine Trial, Backed by $456M BARDA Deal - StockTitan
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - GlobeNewswire
Vaxart, Inc. (NASDAQ:VXRT) Shares Sold by Sio Capital Management LLC - MarketBeat
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside - AOL
VXRT (Vaxart) Enterprise Value : $95.98 Mil (As of Nov. 23, 2024) - GuruFocus.com
B. Riley Has Optimistic Outlook of Vaxart FY2024 Earnings - MarketBeat
COVID-19 vaccine company Vaxart under US federal investigation - Telegrafi
What is B. Riley's Estimate for Vaxart FY2027 Earnings? - MarketBeat
1.08%
2.45%
자본화:
|
볼륨(24시간):